Breaking News, Financial News

J&J 1Q08

J&J 1Q08

1Q Revenues: $16.2 billion (+8%)

1Q Earnings: $3.6 billion (+22%)

Comments: Pharmaceutical sales rose 3% to $6.4 billion, hurt by regulatory and safety issues for Procrit, as well as generic competition for Risperdal, Duragesic and Aciphex. U.S. pharma sales were up 1% to $4.1 billion, while international sales, aided in part by currency rates, were up 8% to $2.4 billion. Global sales of Remicade grew 37% to $1.0 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters